MediPharm Labs (TSE:LABS) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MediPharm Labs Corp. has announced a strategic licensing agreement to acquire exclusive global rights for advanced medical cannabis delivery technology from Remidose Aerosols, including metered dose inhalers and aerosol sublingual sprays. This deal, expected to generate immediate revenue through the servicing of existing Remidose customers, aligns with MediPharm’s innovation strategy in non-smokable, precision-dosed cannabis products and reinforces its global leadership in the pharmaceutical and wellness-focused cannabis sectors.
For further insights into TSE:LABS stock, check out TipRanks’ Stock Analysis page.